Skip to main content

Zonegran Disease Interactions

There are 11 disease interactions with Zonegran (zonisamide).

Major

Carbonic anhy. inhibitors (applies to Zonegran) bone marrow depression/blood dyscrasias

Major Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts, History - Blood Dyscrasias

The use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages. Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported. Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions. A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.

References

  1. (2001) "Product Information. Diamox (acetazolamide)." Lederle Laboratories
  2. (2001) "Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals
  3. (2006) "Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories
Major

Carbonic anhydrase inhibitor anticonvulsants (applies to Zonegran) oligohidrosis/hyperthermia

Major Potential Hazard, Moderate plausibility. Applicable conditions: Fever

Oligohidrosis (decreased sweating) and hyperthermia have been reported in association with the use of some carbonic anhydrase inhibitor anticonvulsants such as topiramate and zonisamide. Most of the reports have been in children. Caution and close monitoring of body temperature is advised when prescribing these drugs, especially in patients with a fever, in hot weather, or if combined with other drugs that predispose to heat related disorders. Zonisamide is not approved for use in pediatric patients in the U.S.

References

  1. (2001) "Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals
  2. (2023) "Product Information. Topamax (topiramate)." Janssen Pharmaceuticals, SUPPL-65
Major

Carbonic anhydrase inhibitors (applies to Zonegran) severe liver disease

Major Potential Hazard, Moderate plausibility.

The use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis. Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients. Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased. A dose reduction might be needed and monitoring of the liver function is recommended.

References

  1. (2001) "Product Information. Diamox (acetazolamide)." Lederle Laboratories
  2. (2001) "Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals
  3. (2006) "Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories
Major

Sulfonamides (applies to Zonegran) hematologic toxicity

Major Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts

The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia, leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia. Acute dose-related hemolytic anemia may occur during the first week of therapy due to sensitization, while chronic hemolytic anemia may occur with prolonged use. Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency should be observed closely for signs of hemolytic anemia. Therapy with sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression. Complete blood counts should be obtained regularly, especially during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.

References

  1. Barak S, Shaked Y, Bar A, Samra Y (1989) "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg, 18, p. 206-7
  2. Chan M, Beale D, Moorhead J (1980) "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract, 34, p. 87-8
  3. Damergis J, Stoker J, Abadie J (1983) "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA, 249, p. 590-1
  4. Finland M, Strauss E, Peterson O (1984) "Sulfadiazine." JAMA, 251, p. 1467-74
  5. Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP (1992) "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol, 19, p. 621-2
  6. Youssef PP, Bertouch JV (1992) "Sulphasalazine induced aplastic anaemia." Aust N Z J Med, 22, p. 391-2
  7. Keisu M, Ekman E (1992) "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol, 43, p. 215-8
  8. "Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.
  9. (2001) "Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories
  10. (2001) "Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc
  11. Peppercorn MA (1984) "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med, 101, p. 377-86
  12. Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ (1985) "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol, 80, p. 118-21
  13. Wheelan KR, Cooper B, Stone MJ (1982) "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med, 97, p. 726-7
  14. Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ (1985) "Thrombocytopenia and sulfasalazine." Ann Intern Med, 102, p. 277-8
  15. Davies GE, Palek J (1980) "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med, 140, p. 1122
  16. Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J (1989) "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol, 16, p. 1166-7
  17. Mitrane MP, Singh A, Seibold JR (1986) "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol, 13, p. 969-72
  18. Mechanick JI (1985) "Coombs' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med, 52, p. 667-70
  19. Betkowski AS, Lubin A (1993) "Sulfamethoxazole-related antiplatelet antibody." Blood, 82, p. 1683
  20. Gales BJ, Gales MA (1993) "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother, 27, p. 1052-4
  21. (2001) "Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn
  22. Bates CM (1996) "HIV medicine: drug side effects and interactions." Postgrad Med J, 72, p. 30-6
  23. (2001) "Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals
  24. Hopkinson ND, Garcia FS, Gumpel JM (1989) "Haematological side-effects pf sulphasalazine in inflammatory arthritis." Br J Rheumatol, 28, p. 414-7
  25. Logan EC, Williamson LM, Ryrie DR (1986) "Sulphasalazine associated pancytopenia may be caused by acute folate deficiency." Gut, 27, p. 868-72
View all 25 references
Major

Sulfonamides (applies to Zonegran) hypersensitivity reactions

Major Potential Hazard, Moderate plausibility. Applicable conditions: Allergies, Asthma, HIV Infection

The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole. Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity. Therapy with sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions. Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis. Sulfonamide therapy should be stopped at once if a rash develops.

References

  1. Johnson M, Goodwin D, Shands J (1990) "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy, 10, p. 413-16
  2. Hofer T, Becker EW, Weigand K, Berg PA (1992) "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol, 15, p. 262-3
  3. Stevenson D, Christie D, Haas J (1978) "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics, 61, p. 864-6
  4. Smith E, Light J, Filo R, Yum M (1980) "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA, 244, p. 360-1
  5. Fischl M, Dickinson G, LaVoie L (1988) "Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for pneumocystis carinii pneumonia in AIDS." JAMA, 259, p. 1185-9
  6. Whittington R (1989) "Toxic epidermal necrolysis and co-trimoxazole." Lancet, 2, p. 574
  7. Kelly W, Dooley D, Lattuada C, Smith C (1992) "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis, 14, p. 1034-9
  8. Horak J, Mertl L, Hrabal P (1984) "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology, 31, p. 199-200
  9. Gibson J (1982) "Recurrent trimethoprim-associated fixed skin eruption." Br Med J, 284, p. 1529-30
  10. Holdcroft C, Ellison R (1991) "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS, 5, p. 1029-42
  11. Steinbrecher U, Mishkin S (1981) "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci, 26, p. 756-9
  12. Rudra T, Webb D, Evans A (1989) "Acute tubular necrosis following co-trimoxazole therapy." Nephron, 53, p. 85-6
  13. Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB (1989) "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest, 95, p. 937-8
  14. Heer M, Altorfer J, Burger H, Walti M (1985) "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology, 88, p. 1954-7
  15. Pisanty S, Brayer L (1965) "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med, 20, p. 154-7
  16. Robson M, Levi J, Dolberg L, Rosenfeld J (1970) "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci, 6, p. 561-6
  17. Finland M, Strauss E, Peterson O (1984) "Sulfadiazine." JAMA, 251, p. 1467-74
  18. Goadsby P, Donaghy A, Lloyd A, Wakefield D (1987) "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med, 107, p. 783-4
  19. Carbone L, Bendixen B, Appel G (1988) "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis, 12, p. 72-5
  20. Tenant-Flowers M, Boyle M, Carey D, et al. (1991) "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS, 5, p. 311-5
  21. Leroux JL, Ghezail M, Chertok P, Blotman F (1992) "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol, 10, p. 427
  22. "Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.
  23. (2001) "Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories
  24. (2001) "Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc
  25. Peppercorn MA (1984) "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med, 101, p. 377-86
  26. Kanner RS, Tedesco FJ, Kalser MH (1978) "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis, 23, p. 956-8
  27. Losek JD, Werlin SL (1981) "Sulfasalazine hepatotoxicity." Am J Dis Child, 135, p. 1070-2
  28. Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D (1984) "Sulfasalazine hepatotoxicity." Am J Gastroenterol, 79, p. 401-2
  29. Yaffe BH, Korelitz BI (1983) "Sulfasalazine pneumonitis." Am J Gastroenterol, 78, p. 493-4
  30. Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS (1986) "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol, 81, p. 205-8
  31. Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y (1985) "Sulfasalazine pneumonitis." Am J Gastroenterol, 80, p. 343-5
  32. Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J (1992) "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol, 87, p. 1654-7
  33. Poland GA, Love KR (1986) "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med, 81, p. 707-8
  34. Hamadeh MA, Atkinson J, Smith LJ (1992) "Sulfasalazine-induced pulmonary disease." Chest, 101, p. 1033-7
  35. Williams T, Eidus L, Thomas P (1982) "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest, 81, p. 766-8
  36. Valcke Y, Pauwels R, Van der Straeten M (1987) "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest, 92, p. 572-3
  37. Taffet SL, Das KM (1983) "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci, 28, p. 833-42
  38. Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H (1986) "Serious complications of sulfasalazine." Dis Colon Rectum, 29, p. 201-2
  39. Sotolongo RP, Neefe LI, Rudzki C, Ishak KG (1978) "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology, 75, p. 95-9
  40. Wang KK, Bowyer BA, Fleming CR, Schroeder KW (1984) "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc, 59, p. 343-6
  41. Haines JD, Jr (1986) "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med, 79, 193-4,
  42. Faintuch J, Mott CB, Machado MC (1985) "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg, 70, p. 271-2
  43. Marinos G, Riley J, Painter DM, McCaughan GW (1992) "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol, 14, p. 132-5
  44. Namias A, Bhalotra R, Donowitz M (1981) "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol, 3, p. 193-8
  45. Gremse DA, Bancroft J, Moyer MS (1989) "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr, 9, p. 261-3
  46. Marinac JS, Stanford JF (1993) "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis, 16, p. 178-9
  47. Rubin R (1994) "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol, 89, p. 789-91
  48. (2001) "Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn
  49. Roujeau JC, Kelly JP, Naldi L, et al. (1995) "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med, 333, p. 1600-7
  50. Bates CM (1996) "HIV medicine: drug side effects and interactions." Postgrad Med J, 72, p. 30-6
  51. Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J (1996) "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis, 34, p. 155-6
  52. Moore RD, Fortgang I, Keruly J, Chaisson RE (1996) "Adverse events from drug therapy for human immunodeficiency virus disease." Am J Med, 101, p. 34-40
  53. (2001) "Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals
View all 53 references
Major

Zonisamide (applies to Zonegran) depression

Major Potential Hazard, Moderate plausibility.

Antiepileptic drugs including zonisamide can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication. Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior. Caregivers and family should be alert for the emergence or worsening of symptoms. Behaviors of concern should be reported immediately to the healthcare providers.

References

  1. (2001) "Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals
Moderate

Antiepileptics (applies to Zonegran) suicidal tendency

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Depression, Psychosis

Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo. AEDs should be administered cautiously in patients with depression or other psychiatric disorders; phentermine-topiramate should be avoided in patients with history of suicidal attempts or active suicidal ideation. The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior. If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.

References

  1. (2002) "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals
  2. (2001) "Product Information. Klonopin (clonazepam)." Roche Laboratories
  3. (2001) "Product Information. Dilantin (phenytoin)." Parke-Davis
  4. (2001) "Product Information. Cerebyx (fosphenytoin)." Parke-Davis
  5. (2001) "Product Information. Mysoline (primidone)." Elan Pharmaceuticals
  6. (2005) "Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group
  7. (2009) "Product Information. Sabril (vigabatrin)." Lundbeck Inc
  8. (2011) "Product Information. Potiga (ezogabine)." GlaxoSmithKline
  9. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  10. (2016) "Product Information. Briviact (brivaracetam)." UCB Pharma Inc
  11. (2018) "Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC
  12. (2020) "Product Information. Xcopri (cenobamate)." SK Life Science, Inc.
  13. (2020) "Product Information. Fintepla (fenfluramine)." Zogenix, Inc
  14. (2022) "Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc
  15. (2022) "Product Information. Diacomit (stiripentol)." Biocodex USA, SUPPL-3
  16. (2023) "Product Information. Qsymia (phentermine-topiramate)." Vivus Inc, SUPPL-23
  17. (2023) "Product Information. Topamax (topiramate)." Janssen Pharmaceuticals, SUPPL-65
View all 17 references
Moderate

Carbonic anhydrase inhibitor anticonvulsants (applies to Zonegran) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

The major route of elimination of carbonic anhydrase inhibitors is through the kidney. These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment.

References

  1. (2001) "Product Information. Diamox (acetazolamide)." Lederle Laboratories
  2. (2001) "Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals
  3. (2023) "Product Information. Topamax (topiramate)." Janssen Pharmaceuticals, SUPPL-65
Moderate

Carbonic anhydrase inhibitors (applies to Zonegran) metabolic acidosis

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Chronic Obstructive Pulmonary Disease, Diarrhea

Reduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors. Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea). The measurement of baseline and periodic serum bicarbonate is recommended. If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.

References

  1. (2001) "Product Information. Diamox (acetazolamide)." Lederle Laboratories
  2. (2001) "Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals
  3. (2023) "Product Information. Topamax (topiramate)." Janssen Pharmaceuticals, SUPPL-65
Moderate

Zonisamide (applies to Zonegran) nephrolithiasis

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Dehydration, History - Nephrolithiasis

The use of zonisamide may infrequently be associated with the development of nephrolithiasis. The reported incidence for clinically possible or confirmed kidney stones was 4.0% (40 of 991 patients) during premarketing use, representing a rate of 34 per 1000 patient-years of exposure (40 patients with 1168 years of exposure). Therapy with zonisamide should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis. Patients who are dehydrated may be at increased risk for the development of nephrolithiasis and should be encouraged to consume additional amounts of liquid during zonisamide therapy.

References

  1. (2001) "Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals
Moderate

Zonisamide (applies to Zonegran) seizures

Moderate Potential Hazard, Moderate plausibility.

The abrupt withdrawal of zonisamide capsules in patients with epilepsy may precipitate the increase of seizure frequency or status epilepticus. Caution is advised when using this drug in patients with seizures. Dose reduction or discontinuation should be done gradually.

References

  1. (2001) "Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals

Zonegran drug interactions

There are 399 drug interactions with Zonegran (zonisamide).

Zonegran alcohol/food interactions

There is 1 alcohol/food interaction with Zonegran (zonisamide).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.